Enicepatide: Clinical Trials

9 trials of Enicepatide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 not yet recruiting, 3 recruiting, 2 completed, 1 active not recruiting. 5 Phase 3, 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 35Recruiting 3, Not yet recruiting 2
Phase 23Completed 2, Not yet recruiting 1
Phase 11Active not recruiting 1

Follow Enicepatide: new trials by email Literature Review of Enicepatide trials Research Report on Enicepatide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease
Enicepatide, Placebo - Overweight, Obesity
Phase 3Not yet recruitingHoffmann-La Roche82002027-01-062026-11-05
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus
Phase 3Not yet recruitingHoffmann-La Roche9482026-12-012026-10-22
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
Petrelintide, Enicepatide, Petrelintide-matching Placebo - Obesity or Overweight
Phase 2Not yet recruitingHoffmann-La Roche4862026-11-302026-11-03
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Enicepatide, Placebo - Obesity, Overweight
Phase 3RecruitingHoffmann-La Roche3002026-07-032026-11-05
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
Enicepatide, Placebo - Healthy Participants
Phase 1Active not recruitingHoffmann-La Roche362026-07-022026-11-05
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Placebo, Enicepatide - Obesity or Overweight, Type 2 Diabetes Mellitus
Phase 3RecruitingHoffmann-La Roche16002026-03-232026-11-09
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Placebo, Enicepatide - Obesity or Overweight
Phase 3RecruitingHoffmann-La Roche20002026-03-162026-11-09
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Placebo, Enicepatide - Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Phase 2CompletedCarmot Therapeutics, Inc.4472024-11-212026-10-28
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
Placebo, Enicepatide - Obesity, Overweight
Phase 2CompletedCarmot Therapeutics, Inc.4692024-08-162026-10-05

Conditions studied

Obesity (7)  ·  Overweight (7)  ·  Diabetes Mellitus, Type 2 (4)  ·  Cardiovascular Diseases (1)

Sponsors

Hoffmann-La Roche (7)  ·  Carmot Therapeutics, Inc. (2)

Countries

China (4)  ·  United States (4)  ·  Argentina (3)  ·  Canada (3)  ·  Mexico (3)  ·  Australia (2)  ·  Brazil (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  India (2)  ·  Italy (2)  ·  Japan (2)  ·  Poland (2)  ·  Puerto Rico (2)

NIH funding

2025 (2)